This update of the 2013 clinical practice guideline provides clinicians with guidance regarding the use of aprepitant and palonosetron for the prevention of acute chemotherapy-induced nausea and vomiting (CINV) in children. The recommendations were based on three systematic reviews.
INTRODUCTION
This focused update of the 2013 Guideline for the Prevention of Acute Nausea and Vomiting due to Antineoplastic Medication in Pediatric Cancer Patients 1 was prompted by the recent publication of several pediatric randomized controlled trials evaluating aprepitant and palonosetron for the prevention of acute chemotherapy-induced nausea and vomiting (CINV). The overall aim of the guideline update is to optimize acute CINV control in children by providing guidance on the use of aprepitant and palonosetron to healthcare professionals who care for children with cancer or for those receiving chemotherapy for hematopoietic stem cell transplant conditioning. This guideline update may be of most interest to physicians, pharmacists, nurse practitioners, physician assistants, and nurses. Optimal acute CINV control is defined as no vomiting, no retching, no nausea, no use of antiemetic agents other than those given for CINV prevention, and no nausearelated change in the child's usual appetite and diet on each day that chemotherapy is administered and for 24 hr after administration of the last chemotherapy agent of the chemotherapy block. Nausea is defined as the subjective sensation that one might vomit. The recommendations of this guideline update, like those of the previous guideline, are most applicable to chemotherapy-naïve cancer patients 1 month to 18 years of age. This update is focused on aprepitant and palonosetron and is provided pending a full guideline update.
METHODS

Guideline panel and health questions addressed
The membership of the interprofessional CINV Guideline Panel and conflict of interest declarations are provided in the online Supplementary Material Section A. No panel member had a conflict of interest that precluded participation. Health questions addressed in the 2013 guideline were reviewed and those relevant to this update were brought forward (Table 1) .
Evidence identification and review
Three systematic reviews were conducted in consultation with a library scientist. The database search strategies, eligibility criteria, and Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flowcharts for each systematic review are provided in the online Supplementary Material Sections B-D. Two reviewers independently screened the titles and abstracts, evaluated the full text of potentially relevant citations for eligibility, and assessed the risk of bias of included randomized trials using the Cochrane Collaboration tool. 2 Disagreements were resolved by a third reviewer. The three systematic reviews were:
a. primary studies of aprepitant or palonosetron describing the rate of CINV control in children;
b. meta-analyses evaluating palonosetron compared to other 5-hydroxytryptamine type 3 (5-HT 3 ) antagonists for acute CINV prophylaxis in adults or children; and c. primary studies describing palonosetron pharmacokinetic disposition.
Evidence tables were compiled to summarize the findings of all included studies and organized by chemotherapy emetogenicity (minimal, low, moderate, and high) based on the pediatric emetogenicity classification guideline 3 or, when this was not possible, by the chemotherapy emetogenicity classification used by the authors of the included studies. For studies where subjects received chemotherapy of different levels of emetogenicity (e.g., highly emetogenic chemotherapy [HEC] or moderately emetogenic chemotherapy [MEC] ) and where study investigators did not report CINV control rates for these two groups separately, the extracted data were categorized under the lower emetogenicity level.
Evidence summaries of adverse events were restricted to those reported in included randomized trials, since adverse event reporting in these studies was more likely to be completed in a systematic fashion.
Recommendations were developed based on the evidence identified from the systematic reviews and refined through panel discussions. The associated potential health benefits versus risks were considered for each recommendation. Strong recommendations (i.e., most individuals should receive the recommended intervention) 4 were made when the panel was certain that the potential benefits of the recommended intervention outweighed the risk of harm. Differences in opinion were resolved by consensus. The quality of evidence and strength of recommendations were assessed using the Grades of Recommendation Assessment, Development and Evaluation system 5, 6 by one author and confirmed through discussion by the remaining panel members. If consensus could not be reached, a decision was made by the majority of panel members by a vote.
External review
A draft version of the guideline was reviewed by international experts in pediatric CINV. The committee considered the responses received before finalizing the recommendations (Supplementary Tables S15   and S16 ).
Guideline updates
A comprehensive update to the 2013 Guideline for the Prevention of Acute Nausea and Vomiting due to Antineoplastic Medication in Pediatric Cancer Patients 1 is planned for 2018.
RESULTS
Results of the searches for the three systematic reviews and their respective evidence tables are presented in the online Supplementary Materials ( Supplementary Fig. S1 -S3, Supplementary Tables S2-S8,   S10 , and S12).
CINV control:
The systematic review of primary papers describing the chemotherapy-induced vomiting (CIV) control rate in children receiving aprepitant or palonosetron identified 2,374 references. Of these, 70 were reviewed in full text and 12 met the criteria for inclusion aprepitant: 5 [7] [8] [9] [10] [11] ; palonosetron: 7 [12] [13] [14] [15] [16] [17] [18] (Supplementary Fig. S1 ). No evidence regarding the use of aprepitant or palonosetron in children receiving chemotherapy of low or minimal emetogenicity was identified.
Between-screener agreement regarding inclusion of full-text articles was almost perfect (kappa = 90.6, 95% confidence interval [CI] 77.7-100%). 19 Tables 2 and 3 summarize the characteristics of the included studies. An assessment of the risk of bias in randomized studies is provided in Supplementary Table S8 . Data extracted with respect to CINV control and adverse events are presented in Supplementary   Tables S2-S7 .
Adverse events: Two and four fully published, randomized controlled pediatric trials evaluating aprepitant 7, 10 (202 children) and palonosetron 12, 14, 16, 17 (421 children), respectively, were included in the adverse event summary. The incidence of drug-related adverse events reported in these trials was less than 5%; serious drug-related adverse events were reported even less frequently (Supplementary   Tables S6 and S7 Table S10 ).
Pharmacokinetic disposition of palonosetron:
Twenty articles evaluating palonosetron pharmacokinetics were included in this systematic review [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] (Supplementary Table S12 ).
The recommendations for the prevention of acute CINV in children receiving HEC or MEC are summarized in Table 1 The dexamethasone dose administered in this trial was not standardized and the proportion of children in this subset who received it is unknown. The third was a small crossover study that found no difference in CIV control rates in children receiving ondansetron plus dexamethasone plus either olanzapine or aprepitant (77 vs. 79%; panel cal-
Palonosetron: A meta-analysis 20 and three pediatric randomized Two of the pediatric trials evaluated palonosetron monotherapy versus ondansetron monotherapy. 16, 17 One observed similar rates of complete acute CIV control between the study arms (70 vs. 65%; P = 0.633), 17 whereas the second observed improved CIV control in the palonosetron study arm (92 vs. 72%; panel calculated P = 0.017; panel calculated 95% CI of the difference between groups: 4-36%). 16 The third pediatric trial used a noninferiority design. The use of dexamethasone in this trial was discretionary and, if given, the dose was not standardized. High-dose palonosetron was found to be noninferior to ondansetron with respect to complete acute response rates in children receiving HEC or MEC. 12 Although not a study aim, the rates of complete acute response in children receiving HEC were: highdose palonosetron 43%, low-dose palonosetron 51%, and ondansetron
41%.
Summary: In developing these recommendations, the trial demonstrating increased complete CIV control rates in children given aprepitant in combination with a 5-HT 3 antagonist and dexamethasone was valued highly by the panel. 10 Aprepitant is not recommended for use in children less than 6 months of age because it has not been studied in this age group for the purpose of CINV prophylaxis. Aprepitant, a moderate CYP3A4 inhibitor, continues to be recommended for indirectly supports the use of a 5-HT 3 antagonist plus aprepitant.
Palonosetron: These recommendations were informed by the previously described adult-focused meta-analysis 41 and three pediatric randomized trials. 12, 16, 17 The meta-analysis 20 observed a greater likelihood of preventing acute CIV in patients receiving palonosetron alone compared to monotherapy with other 5-HT 3 antagonists (odds ratio: 1.52; 95% CI: 1.15-2.02). Two of the pediatric randomized trials, 16, 17 one of which was included in the meta-analysis, 16 compared palonosetron monotherapy versus ondansetron monotherapy. These trials differed substantially in their definitions of the acute phase. The trial that likely enrolled children receiving multiple-day therapy 17 reported complete CIV control rates achieved during the entire acute phase (i.e., more than 24 hr in duration). No difference was observed between the study arms (palonosetron vs. ondansetron: 70 vs. 65%; P = 0.633). In contrast, the second trial 16 dexamethasone cannot be given is also provided in the noninferiority trial mentioned previously. 12 Although not a primary study aim, rates of complete acute control for the subset of children who received 1-day HEC and who did not receive dexamethasone were: low-dose palonosetron 61%, high-dose palonosetron 60%, and ondansetron
42%.
Summary: In developing Recommendation 1.4, value was placed on improved CIV control reported in a subset of patients within a larger randomized controlled trial who received ondansetron plus aprepitant. 7 As explained earlier, aprepitant is not recommended for children less than 6 months old. In recommending palonosetron as the 41 This analysis was not presented separately for patients receiving MEC.
Health Question 2: What pharmacological interventions provide optimal control of acute CINV in children receiving MEC?
The previously described noninferiority trial provided complete CIV control rates in the subset of 339 patients receiving MEC. 12 Complete acute CIV control rates of 63, 60, and 67% were observed in these children receiving high-dose palonosetron and low-dose palonosetron or ondansetron, respectively. An unknown number of children in each study arm also received a nonstandardized dose of dexamethasone.
In addition, ondansetron versus palonosetron was evaluated in a randomized control trial in children receiving HEC (122 cycles) or MEC (38 cycles). However, results were not reported separately for these groups. 14 Children receiving HEC also received dexamethasone in this trial. Complete acute CIV control rates were comparable between the two study arms (70 vs. 75%; P value = 0.479).
Furthermore, results from the three single-arm observational studies also described good CIV control rates with palonosetron. The two prospective studies 13, 18 reported complete acute CIV control rates of 84 and 98%, respectively, in children receiving MEC and palonosetron. It is important to note that children who participated in this trial received either HEC or MEC and an unknown proportion also received dexamethasone for CINV prophylaxis. Furthermore, the noninferiority trial described earlier reported complete acute CIV control rates in the very small subset of children receiving 1-day MEC with dexamethasone as follows: low-dose palonosetron 57%; high-dose palonosetron 88%; and ondansetron 73%. 12 Complete acute CIV control rates reported in prospective observational studies for children receiving MEC with palonosetron monotherapy ranged from 68 to 91%. 13, 15, 18 Summary: The panel developed Recommendations 2.2-2.4 with the appreciation that children who cannot receive dexamethasone are more vulnerable to breakthrough and refractory CINV. These recommendations draw on the evidence of efficacy in children receiving HEC.
Value was also placed on the large pediatric randomized controlled trials describing CIV control in the subsets of children receiving MEC and ondansetron plus aprepitant 7 and palonosetron monotherapy. 12 Given the broad range of emetogenicity risk classified as MEC (30-90%), 3 the panel recognizes that clinicians may wish to reserve palonosetron for children who cannot receive dexamethasone and are about to receive chemotherapy with an emetogenicity risk at the higher end of the MEC range.
The panel also considered the inclusion of antiemetic agents such as chlorpromazine, metoclopramide, and nabilone for use when aprepitant is not an option. However, the lack of direct evidence to support the efficacy and safety of these agents in children less than 6 months and the absence of high-quality evidence describing their efficacy in combination with a 5-HT 3 antagonist dissuaded the guideline panel from recommending their use.
Recommendations 2.2-2.4 are weak recommendations because uncertainty exists regarding the extent of the improvement in CIV control that can be achieved with the implementation of these recommendations due to the lack of direct supporting evidence. Summary: This recommendation places a high value on the dose simulation information discussed within a pediatric randomized control trial 7 and on evidence that this dose improves CIV control in children during the first 24 hr after the receipt of HEC or MEC.
What doses
The recommended dose is in agreement with the aprepitant dose approved for pediatric use by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). 42, 43 Questions, however, remain regarding the optimal aprepitant dose in children receiving multiple-day chemotherapy and whether a single aprepitant dose would be sufficient for children receiving singleday chemotherapy. As a result of these uncertainties, this is a weak recommendation.
Recommendation 3.2:
We suggest the following palonosetron dose mg/kg/dose IV q4h × three doses. 12 It is recommended that adolescents 17-18 years of age receive the licensed adult palonosetron dose. [44] [45] [46] The palonosetron dose recommended for patients 17 years of age and older is based on a dose-finding study that concluded that 0.003 mg/kg was the lowest effective dose in adults. 34 It is notable that adults weighing less than 83 kg who receive the approved adult palonosetron dose (0.25 mg IV) receive more than 0.003 mg/kg.
The pediatric palonosetron dose approved by the FDA and EMA 44, 46 is six times greater than the recommended adult dose. Since pediatric dosing is often calculated to approximate the dose intensity (e.g., area under the curve from time 0 to infinity [AUC 0-inf ], maximum concentration, and time above a threshold concentration) achieved in adults, a systematic review of studies that describe palonosetron pharmacokinetic disposition in adults and children was undertaken.
Findings from this review confirmed that when single palonosetron doses of 0.02 mg/kg are given to children, the dose intensity achieved exceeds that achieved when palonosetron 0.003 mg/kg doses are given to adults (Supplementary Table S12 ).
No palonosetron pharmacokinetic parameter is predictive of CINV outcomes in adults. 47 However, a logistical regression exposurerelationship model developed using pediatric data noted increased CIV control (no emetic episode and no use of rescue medication during the first 24 hr after the start of emetogenic chemotherapy) with increasing palonosetron AUC 0-inf . This effect plateaued at an AUC 0-inf of approximately 100 g h/L, which approximates the AUC 0-inf achieved after administration of 0.02 mg/kg/dose in children. 48 Since the emetogenicity of the chemotherapy received by the patients included in the model was not reported, it is not possible to determine if the association between CIV control and palonosetron AUC applies to both MEC and HEC.
Flat or nonweight-based palonosetron doses have been shown to be effective in children (Supplementary Table S14 ). In two pediatric randomized controlled trials that evaluated single IV palonosetron doses of 0.25 mg, it was possible to calculate the weight-based palonosetron dosing range. 16, 17 One trial found acute CIV control to be comparable between patients receiving palonosetron (dose range:
0.03-0.09 mg/kg) and those receiving ondansetron (70 vs 65%; p=0.633). 17 In the other trial, CIV control in the palonosetron arm (dose range: 0.003-0.019 mg/kg/dose) was superior to that in the ondansetron study arm (92 vs. 72%; P = 0.0092). 16 Another pediatric randomized trial 14 and three single-arm studies 13 [13] [14] [15] [16] 18 it is unclear if palonosetron 0.02 mg/kg is required to achieve optimal acute CIV control in children or if a lower dose could achieve comparable outcomes. In addition, optimal palonosetron dosing in children receiving multiple-day chemotherapy is unknown and is an important research gap. This is a weak recommendation because the panel is not certain that a palonosetron dose of 0.02 mg/kg is warranted for MEC and HEC.
Implementation considerations
While motivated by CINV control optimization and safety, the panel recognized that the cost of aprepitant and palonosetron may be a barrier to the implementation of these recommendations. In jurisdictions where cost is a barrier to using palonosetron 0.02 mg/kg/dose and compliance with the dose approved by regulatory authorities is not a concern, it may be reasonable to initiate palonosetron at the recommended dose with a patient's first chemotherapy block and, depending on the patients' CINV control, to administer a lower dose with a future chemotherapy block. Administration of ondansetron or granisetron may also be reasonable. Patient and institutional values, preferences and resources should be considered when implementing guideline recommendations.
CONCLUSIONS
Recommendations for the prevention of acute CINV in children have been updated (Table 1 and Supplementary Table S17 ). Significant changes have been made to the recommendations in light of new evidence supporting the use of aprepitant and palonosetron in children. However, extensive evidence gaps remain (Table 4) .
Continual appraisal of the evidence and prospective evaluation of patient outcomes that are achieved with the implementation of these recommendations are required. Furthermore, to ensure that control of acute CINV in children is optimized, future work must address critical evidence gaps. 
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